Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.47 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.46 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.46 |
| ▸ | SCD | O00767 | 12/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187372 | 0.99 | SCD (0.51) | SCDACHEDRD2SLC6A4HTT | |
| SCHEMBL29688619 | 0.99 | SCD (0.51) | SCDACHEDRD2SLC6A4HTT | |
| Hydrochloric Acid SCHEMBL531052 | 0.89 | ACHE (0.60) | SCDACHEDRD2SLC6A4 | |
| SCHEMBL461287 | 0.87 | ACHE (0.61) | SCDACHEDRD2SLC6A4 | |
| SCHEMBL7726651 | 0.84 | ACHE (0.55) | ACHEDRD2SLC6A4 | |
| Hydrochloric Acid SCHEMBL23581610 | 0.83 | HTR2A (0.45) | SCDDRD2HTT | |
| Hydrochloric Acid SCHEMBL29891155 | 0.83 | HTR2A (0.45) | SCDDRD2HTT | |
| Hydrochloric Acid SCHEMBL604319 | 0.83 | NPC1 (0.43) | — | |
| Hydrochloric Acid SCHEMBL11154766 | 0.83 | ESR1 (0.45) | SCD | |
| SCHEMBL8920018 | 0.82 | SCD (0.54) | SCDACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-3768684-B1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN LA ROCHE (CH) | 2023-02-22 | — | — | EP | disclosed |
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3211126-B1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X CHEM INC (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3653763-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X-Chem, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3211126-A1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X-Chem, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2396459-B1 | METHODS OF CREATING AND SCREENING DNA-ENCODED LIBRARIES | X-CHEM INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9238658-B2 | Substituted piperidinyl-carboxamide derivatives useful as SCD 1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-19 | — | — | US | disclosed |
| US-9102669-B2 | Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-11 | — | — | US | disclosed |
| US-20140371220-A1 | SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-18 | — | — | US | disclosed |
| EP-0080104-B1 | 3-(4-PIPERIDYL)-1,2-BENZISOXAZOLES, PROCESS FOR THE PREPARATION THEREOF, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-12-14 | — | — | EP | disclosed |
| EP-0079564-B1 | 3-(1-SUBSTITUTED-4-PIPERIDYL)-1,2-BENZISOXAZOLES, A PROCESS FOR THE PREPARATION THEREOF, A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND THEIR USE AS MEDICAMENTS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1986-03-19 | — | — | EP | disclosed |
| US-4528376-A | 3-(4-Piperidyl)-1,2-benzisoxazoles | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1985-07-09 | — | — | US | disclosed |
| US-4469869-A | ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1984-09-04 | — | — | US | disclosed |
| US-4408053-A | ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1983-10-04 | — | — | US | disclosed |
| US-4408054-A | ANALGESTICS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1983-10-04 | — | — | US | disclosed |
| EP-0080104-A2 | 3-(4-Piperidyl)-1,2-benzisoxazoles, process for the preparation thereof, and a pharmaceutical composition comprising the same | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1983-06-01 | — | — | EP | disclosed |
| EP-0079564-A1 | 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles, a process for the preparation thereof, a pharmaceutical composition comprising the same, and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1983-05-25 | — | — | EP | disclosed |
| US-4355037-A | ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS (US) | 1982-10-19 | — | — | US | disclosed |
| US-4352811-A | NEUROLEPTIC AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1982-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107920-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | ACHE 170/4885DRD2 3496/4885SLC6A4 4841/4885 |
| US-20140371220-A1 | SUBSTITUTED PIPERIDINYL-PYRIDAZINYL DERIVATIVES USEFUL AS SCD 1 INHIBITORS | SCD, SCD5, PLIN1 | ACHE 4254/4885DRD2 1810/4885SLC6A4 4001/4885 |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | ACHE 170/4885DRD2 3496/4885SLC6A4 4841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.